AC Immune
Piergiorgio Donati currently serves as Chief of Technical Operations Officer at AC Immune since June 2018, with previous roles including VP Technical Operation and Program Management and Director of Global Program Management, focusing on coordinating global program management activities and enhancing project management expertise. Prior to this, Piergiorgio held positions at Glenmark Pharmaceuticals as Head of CMC Program Development for Biologics, driving the management of CMC projects, implementing strategies, and ensuring compliance with regulations. Experience also includes leading CMC programs at Merck Group, managing manufacturing and project management at AC Immune, and introducing project management platforms at Abiogen. Earlier roles encompassed developing biotech products at Lab. SERONO S.A. and Serono, where formulation development was a primary focus. Piergiorgio holds a degree from Technical Institute "G.L. Bernini".
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.